Payment overview · 2025
General Payments
$1,055.12
62 reported records · 19 companies
Healthcare provider profile · identity verified
Charlene Reshell Locklear, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LUMBERTON, NC · NPI 1083875793
Verified facts
What the public records show
CMS Open Payments records show Charlene Reshell Locklear, M.D. received $1,055.12 in general payments during 2025 across 62 reported records.
ABBVIE INC. accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $258.39 | 24.5% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $157.77 | 14.9% | 5 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $115.39 | 10.9% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.69 | 6.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.46 | 6.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $48.48 | 4.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.42 | 4.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $41.08 | 3.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.20 | 3.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.84 | 3.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.72 | 2.7% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $27.40 | 2.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.84 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.40 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.02 | 2.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.22 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.00 | 1.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.28 | 1.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.52 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,055.12 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $202.89 | 16 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.01 | 3 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $115.39 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $104.50 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $94.32 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $65.69 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $57.60 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $48.79 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $48.48 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $41.08 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.84 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.19 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.72 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.72 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.55 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $27.40 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $6.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 166 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 87 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 160 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 52 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
87 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
166 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
18 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
166 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 493 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 423 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 395 | 114 |
| Losartan Potassium | Losartan Potassium | 385 | 99 |
| Lisinopril | Lisinopril | 376 | 98 |
| Gabapentin | Gabapentin | 375 | 88 |
| Omeprazole | Omeprazole | 366 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 307 | 74 |
| Furosemide | Furosemide | 303 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 259 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 62 |
| Sertraline Hcl | Sertraline Hcl | 203 | 48 |
| Potassium Chloride | Potassium Chloride | 187 | 53 |
| Trazodone Hcl | Trazodone Hcl | 187 | 52 |
| Simvastatin | Simvastatin | 173 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 171 | 35 |
| Mirtazapine | Mirtazapine | 171 | 33 |
| Jardiance | Empagliflozin | 166 | 38 |
| Metformin Hcl | Metformin Hcl | 165 | 46 |
| Glipizide Er | Glipizide | 160 | 43 |
| Ozempic | Semaglutide | 160 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 156 | 44 |
| Montelukast Sodium | Montelukast Sodium | 153 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 43 |
| Tramadol Hcl | Tramadol Hcl | 150 | 45 |
| Allopurinol | Allopurinol | 135 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 44 |
| Carvedilol | Carvedilol | 132 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 42 |
| Metformin Hcl Er | Metformin Hcl | 125 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 121 | 24 |
| Famotidine | Famotidine | 113 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 37 |
| Eliquis | Apixaban | 105 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 21 |
| Spironolactone | Spironolactone | 90 | 21 |
| Ezetimibe | Ezetimibe | 88 | 24 |
| Buspirone Hcl | Buspirone Hcl | 87 | 20 |
| Linzess | Linaclotide | 87 | 22 |
| Lorazepam | Lorazepam | 87 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 32 |
| Meloxicam | Meloxicam | 86 | 33 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 82 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 20 |
| Farxiga | Dapagliflozin Propanediol | 78 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 19 |
| Alendronate Sodium | Alendronate Sodium | 74 | 19 |
| Alprazolam | Alprazolam | 74 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 74 | 13 |
| Pregabalin | Pregabalin | 74 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 14 |
| Donepezil Hcl | Donepezil Hcl | 69 | 25 |
| Prednisone | Prednisone | 69 | 48 |
| Bupropion Xl | Bupropion Hcl | 67 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 17 |
| Mounjaro | Tirzepatide | 60 | suppressed |
| Clonazepam | Clonazepam | 59 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 14 |
| Nystatin | Nystatin | 56 | 20 |
| Memantine Hcl | Memantine Hcl | 55 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Rybelsus | Semaglutide | 52 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 14 |
| Levetiracetam | Levetiracetam | 50 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 18 |
| Sucralfate | Sucralfate | 46 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 17 |
| Estradiol | Estradiol | 44 | 12 |
| Nifedipine Er | Nifedipine | 44 | 12 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | 11 |
| Fluconazole | Fluconazole | 39 | 28 |
| Glimepiride | Glimepiride | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 16 |
| Atenolol | Atenolol | 38 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 26 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | 13 |
| Naproxen | Naproxen | 34 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 14 |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 33 | 14 |
| Lidocaine | Lidocaine | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 14 |
| Topiramate | Topiramate | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 13 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 18 |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Kerendia | Finerenone | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | suppressed |
| Dexamethasone | Dexamethasone | 20 | 16 |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 17 |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Euthyrox | Levothyroxine Sodium | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 13 | suppressed |
| Levoxyl | Levothyroxine Sodium | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Rifampin | Rifampin | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,055.12 · 62 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, GEMTESA, JARDIANCE, Kerendia, Korlym, LEQVIO, LINZESS, NUZYRA, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XHANCE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error